Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare ... (rety by this cautionarystatement and Ami...)

(Date:11/20/2008)...irstCall/ -- Duska Therapeutics,Inc., (OTC Bulle...itted its,pivotal Phase 3 ATPace clinical trial p...sment (SPA) procedure with the U.S. Food and Drug ...g an agreement with the FDA, Duska intends to init...-controlled and randomized Phase 3,clinical trial...

(Date:11/20/2008)...wire/ -- The Scandinavian-based drug,development ...tudies on its,lead antimicrobial candidate LTX-10...ies showed that the novel lytic peptidomimetic has...ly better towards killing Staphylococcus,aureus a...ard drugs. In,addition to this it has proven effe...

(Date:11/19/2008)...gs on critical enzyme,s regulation may hold key to...orders , , MEMPHIS, Tenn., Nov. 19 /PRNewsw...n,s Research Hospital have gained new insights int...s called calpains. , , As the cell,s molec...ular processes, including the movement of cells in...

(Date:11/18/2008)...ll/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialty...t Company,and Sosei Group Corporation ("Sosei"; ... biopharmaceutical company, today announce that Ne...inical efficacy data for NSL-043/SD118.,This inve...athic pain and has,successfully completed Phase I...

Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2 Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3 Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4 Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2 New Insight Into the Controls on a Go-To Enzyme 2 New Insight Into the Controls on a Go-To Enzyme 3 Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2 Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3 Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year 21364 1 Industrial Control Repair Named Honda of America Manufacturings 2007 Supplier of the Year 21364 2 Low Vitamin D Levels May Boost Mens Heart Attack Risk 21362 1 Phase 3 results for alogliptin 21359 1 Phase 3 results for alogliptin 21359 2 Phase 3 results for alogliptin 21359 3 Public Invited to Learn to Work Safe Live Well During Safety Day n June 11 21356 1

[0] Duska Therapeutics Applies for Phase 3 Special Protocol Assessment [0] Lytix Presents LTX-109 Anti-Microbial Data at ICAAC [0] New Insight Into the Controls on a Go-To Enzyme [4] Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting

...d Stability,Significantly Longer than Placebo and ...e with Placebo , MARIETTA, Ga. and COLLEGEVILLE, P...yeth Pharmaceuticals, a division of Wyeth,(NYSE:WY...lts on,bifeprunox, an investigational treatment fo...ay at the 2007 annual meeting of,the American Psyc...

...e as Future-Generation,Technology, BARCELONA, Spai...oday announced positive results from ABSORB, the w...and performance of a fully,bioabsorbable drug elut...rtery disease. Nine-month results from the first 3...roPCR meeting,demonstrated no stent thrombosis an...

Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2 New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3 New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4 New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5 Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2 Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3

New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

(Date:11/21/2008)...swire/ -- The University of Texas M. D. Anderson...tive effort to eradicate breast cancer in Panama t... and Research of the Americas today at an event wi..., and Vivian Fernandez de Torrijos, the First Lady...he initiative are the U.S. Department of State and...

(Date:11/21/2008)... -- NursingCenter.com, the premier site,for onlin...ontent, has been,updated to improve the interacti...owered by Lippincott Williams & Wilkins (LWW),...iewed continuing education activities and free,ac...nursing journals.,Lippincott Williams & Wilki...

(Date:11/21/2008)...e-USNewswire/ -- U.S. News & World Report and ...) ranked BlueChoice(R) HealthPlan of South Carolin...TM), published in U.S. News & World Report,s i...nking ranks the nation,s best health plans based o...ccreditation scores. NCQA and U.S. News & Worl...

(Date:11/21/2008)...ewswire-FirstCall/ -- Today, prescription drugs ar...ating 88 percent of patients suffering chronic con...a chronic condition account for 96 percent of all ...edical costs. A proprietary new pharmacy model de..., Inc. (NYSE: MHS ) significantly reduces critic...

Breaking Medicine News(10 mins):Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2 Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3 Health News:NursingCenter.com Launches New Features to Improve User Experience 2 Health News:NursingCenter.com Launches New Features to Improve User Experience 3 Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5 Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6

[0] First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama [0] NursingCenter.com Launches New Features to Improve User Experience [0] BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans [0] New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes

...in long-term weight reduction and post potential h...e than a short time, accordinhg to an advisory fro...ittee in Circulation published in: Journal of the ...e diets increase fat intake and reduce nutritional...

...sorder (ADHD) who use stimulants like Ritalin are ...he study in rats suggests that stimulant treatment... cocaine in adulthood. // Many children and teens...medication, the best-known being Ritalin. These dr...

...y not only an effective treatment for malaria, the...ears to be similar to the mechanism they use to f...f Toronto report these findings at the 50th Annual...opical Medicine and Hygiene in Atlanta.// The comp...

...ell damage from long-term use of the party drug ec...ey stop taking the drug. Studies have shown that t...as MDMA, can damage nerve endings that release ser...mory, sleep and sex. The drug also appears to dama...

Other Medicine News:Health News:High-protein diets may pose health risks 2

High-protein diets may pose health risks Ritalin May Lower Cocaine Abuse Garlic fights malaria and cancer Women more susceptible to brain damage from ecstasy

Supreme and Response catheters comprise the world's broadest line of fixed-curve catheters available for electrophysiology procedures. Their advanced catheter design and materials technology provide

Lumenis 1000 Integrated Slit Lamp Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multi

Selecta Trio The pinnacle in the family, combining the Nd:YAG, diode-pumped solid-state (DPSS) 532 Photocoagulator and Q-switched frequency-doubled 532nm laser (SLT) and offering maximum flexibility

Medicine Products:

Supreme Catheters Response™ Catheter Lumenis 1000 Integrated Slit Lamp Selecta Trio Photocoagulator and SLT Combination Laser

Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare ...(rety by this cautionarystatement and Ami...),Health